Suven Life Sciences Ltd (SUVEN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Suven Life Sciences Ltd on NSE and BSE, with an AI summary of each filing.
SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited financial results ....
Intimation · 05 Nov 2026, 5:30 am
Suven Life Sciences Board Meeting on 5th Nov'26 to Consider Q2 Results Suven Life Sciences Limited has scheduled a Board of Directors meeting for 5th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with insider trading regulations, the trading window for dealing in company securities has been closed since 1st Oct'26 and will remain closed until 48 hours following the declaration of the financial results.
Please find enclosed the News release
Press Release · 03 Sept 2026, 5:26 pm
Report of Scrutinizer
Annual General Meeting · 25 Aug 2026, 11:57 pm
Suven Life Sciences AGM: All Resolutions Passed With Overwhelming Majority Suven Life Sciences announced that all resolutions at its 37th AGM on 25 Aug '26 were passed with the requisite majority. Key approvals include the adoption of FY26 financial statements, re-appointment of directors, a related party transaction for Dr. Madhavi Jasti's appointment in overseas subsidiaries, and variation in the utilization of funds from a preferential issue. The RPT resolution saw promoters abstain, while non-promoter votes passed it with 99.826% approval. All other resolutions received over 99.98% votes in favor, demonstrating strong shareholder support.
Outcome of 37th Annual General Meeting
Annual General Meeting · 25 Aug 2026, 11:54 pm
Monitoring Agency Report for the quarter ended 30th June, 2026
Others (Uncategorized) · 11 Aug 2026, 6:03 pm
Suven Life Sciences: Utilization of Preferential Issue Proceeds for Q1FY27 As of 30th Jun'26, Suven Life Sciences has utilized ₹40,950.29 lakhs (47.7%) of its ₹85,764.02 lakhs preferential issue proceeds. Key expenditures were ₹27,242.87 lakhs for clinical development via its subsidiary, ₹5,187.23 lakhs for Drug Discovery R&D, and ₹4,960.94 lakhs for a new R&D center. Unutilized proceeds of ₹44,813.73 lakhs are held in debt funds and fixed deposits. There are no deviations from the stated objects of the issue, and utilization is in line with the offer document.
Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026
Outcome · 06 Aug 2026, 6:20 pm
Suven Life Sciences Q1FY27: Revenue Jumps, But Higher R&D Costs Widen Losses Suven Life Sciences reported Q1FY27 consolidated results for the quarter ending 30-Jun'26. Revenue grew 351% YoY to ₹1,108.94 lakhs, driven by a surge in other income. However, a significant 198% YoY increase in R&D expenses to ₹12,383.10 lakhs pushed total expenses to ₹13,869.97 lakhs. This resulted in a net loss of ₹12,761.03 lakhs, widening from a loss of ₹5,151.69 lakhs in the prior year's quarter. Consolidated EPS stood at ₹(4.84). Key pipeline update: SUVN-502 reached 95% enrollment for its Phase 3 trial.
Un-audited Financial results for the quarter ended 30th June, 2026
Financial Result · 06 Aug 2026, 6:17 pm
Suven Life Sciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 357 (+91.0% YoY | +134.6% QoQ) ■ EBITDA: -13,250 (-161.1% YoY | -161.7% QoQ) ■ EBITDA Margin (%): -3,716 (-99732 bps YoY | -38503 bps QoQ) ■ PAT: -12,761 (-147.7% YoY | -179.9% QoQ) ■ EPS (INR): -4.84 (-105.1% YoY | -139.6% QoQ)
Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Intimation · 06 Aug 2026, 5:30 am
Suven Life Sciences Board Meeting on Aug 6th to Approve Q1 FY27 Results Suven Life Sciences has scheduled a Board of Directors meeting on 6th Aug'26 to consider and approve the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th Jun'26. In connection with this, the company's trading window for insiders has been closed since 1st Jul'26 and will reopen 48 hours after the financial results are declared. This meeting is a key event for the upcoming earnings announcement and potential stock price movement.
Letter to Shareholders regarding Annual Report FY 2025-26
Annual Report · 30 Jul 2026, 5:37 pm
Business Responsibility and Sustainability Report (BRSR) for FY 2025-26
Others (Uncategorized) · 30 Jul 2026, 5:28 pm
Suven Life Sciences Business Responsibility and Sustainability Report for FY26 Suven Life Sciences filed its Business Responsibility and Sustainability Report for FY26 on 30 Jul'26. The company derives 100% of its turnover from scientific R&D, with exports contributing 70%. For FY26, total energy consumption was 6,635.70 gigajoules, up from 5,606.06 in FY25, while total water withdrawal increased to 2,007.5 kilolitres from 1,825. Employee attrition for FY26 was 9.28%, down from 19% in FY25. The company reported zero complaints related to sexual harassment, child labor, or data privacy. All investments were made in related parties.
Notice of the 37th Annual General Meeting (AGM) of the Company
Annual General Meeting · 30 Jul 2026, 5:18 pm
Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) of the Company
Others (Uncategorized) · 30 Jul 2026, 5:05 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 21 Jul 2026, 1:05 am
Promoter Stake in Suven Life Sciences Diluted Due to Warrant Conversion and ESOPs Promoter group Jasti Property and Equity Holdings' stake in Suven Life Sciences has been diluted from 70.15% to 65.47% as of 20-Jul'26. This dilution follows an increase in the company's paid-up equity capital. The change was triggered by a preferential allotment of 1,85,70,133 shares to non-promoters upon warrant conversion on 08-Jul'26, and the allotment of 2,71,970 shares under an employee stock option scheme. The total equity share capital increased from 26.40 crore to 28.26 crore shares.
Interaction with Investors and Analysts
Intimation · 14 Jul 2026, 5:36 pm
Suven Life Sciences to Hold Investor & Analyst Meeting Suven Life Sciences has scheduled an in-person meeting with investors and analysts on 17 Jul'26 in Mumbai. The meeting format will be group and one-on-one sessions. The company has explicitly stated that no unpublished price-sensitive information will be disclosed during the interaction. The schedule is subject to potential changes by either the investors or the company.
Please find enclosed News Release of our company
Press Release · 10 Jul 2026, 5:54 pm
Suven Life Sciences to Present Alzheimer's Pipeline Updates at AAIC-2026 Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) in London from 12-15 Jul'26. Key presentations include updates on the global Phase-3 study of Masupirdine for agitation in Alzheimer's dementia and the Phase-2 clinical development program for Usmarapride. The company will also showcase data for other CNS pipeline candidates, including SUVN-I6107 and SUVN-L1101142. Suven aims to engage with investigators and explore strategic partnering opportunities for its clinical-stage CNS portfolio.
Revised outcome of the meeting of Board of Directors - Incorporation of Wholly owned Subsidiary (WOS) in Singapore
Outcome · 08 Jul 2026, 10:22 pm
Suven Life Sciences Allots Shares, Incorporates Subsidiary in Singapore Suven Life Sciences' board on 08 Jul'26 approved the allotment of 1.86 crore equity shares at Rs. 134 each to non-promoter entities upon warrant conversion, raising Rs. 248.84 crore. Consequently, paid-up capital increased to 28.26 crore shares. The board also approved incorporating a wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore with an investment of up to USD 100 million. Additionally, the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second five-year term was approved.
Incorporation of Wholly owned Subsidiary (WOS) in Singapore
Others (Uncategorized) · 08 Jul 2026, 6:40 pm
Suven Life Sciences Board Approves Warrant Conversion and New Subsidiary Suven Life Sciences' board on 08 Jul'26 approved allotting 1.857 crore equity shares at Rs. 134 each upon conversion of warrants, raising Rs. 248.84 crore. The allotment to 17 non-promoter entities increases paid-up capital to 28.26 crore shares. The board also approved incorporating a wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore with a planned investment of USD 100 Mn. Additionally, Dr. Vajja Sambasiva Rao was re-appointed as a Non-Executive Independent Director for a five-year term starting 21 Jan'27.
Re-appointment of Dr. Vajja Sambasiva Rao effective from January 21, 2027 for a second term of 5(five) years
Change in Management · 08 Jul 2026, 6:35 pm
Suven Life Sciences: Preferential Allotment, Subsidiary Incorporation, and Director Re-appointment On 08 Jul'26, Suven Life Sciences' board approved the allotment of 1,85,70,133 equity shares at Rs. 134/share upon conversion of warrants, raising Rs. 248.84 Cr. This increases the paid-up capital to Rs. 28.26 Cr. The board also approved incorporating a wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore with a planned investment of USD 100 Mn. Additionally, Dr. Vajja Sambasiva Rao was re-appointed as a Non-Executive Independent Director for a five-year term starting 21 Jan'27, subject to shareholder approval.
Allotment of 18570133 Equity shares of the Company on preferntial basis upon conversion of 18570133 fully paid warrants
Others (Uncategorized) · 08 Jul 2026, 6:27 pm
Suven Life Sciences Board Approves Warrant Conversion and New Singapore Subsidiary On 08 Jul'26, Suven Life Sciences' board approved allotting 1.86 crore equity shares at Rs. 134 each to non-promoters upon conversion of warrants, raising Rs. 248.84 crore. Consequently, the paid-up equity share capital increased from Rs. 26.40 crore to Rs. 28.26 crore. The board also approved the re-appointment of an Independent Director and the incorporation of a wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore. The new clinical-stage biopharma subsidiary will involve an investment of USD 100 million.
Outcome of Board Meeting
Others (Uncategorized) · 08 Jul 2026, 6:21 pm
Suven Life Sciences Board Approves Preferential Allotment and New Singapore Subsidiary Suven Life Sciences' board on 08 Jul'26 approved allotting 1.86 crore equity shares at Rs. 134 each to non-promoters upon warrant conversion, raising Rs. 248.84 Cr. This increases paid-up capital to 28.26 crore shares. The board also approved incorporating a wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore with an investment of up to USD 100 Mn. Additionally, Dr. Vajja Sambasiva Rao was re-appointed as a Non-Executive Independent Director for a second five-year term, effective 21 Jan'27.
Allotment of 2,71,970 Equity shares upon exercise of vested options under SLSL ESOP 2020 Scheme
Others (Uncategorized) · 22 Jun 2026, 8:53 pm
Suven Life Sciences Allots Equity Shares Under ESOP 2020 On 22 Jun'26, Suven Life Sciences allotted 2,71,970 equity shares under its SLSL ESOP 2020 scheme. The shares have a face value of Rs. 1 and were issued at an exercise price of Rs. 55 each, including a premium of Rs. 54. Consequently, the company's paid-up equity share capital increased from INR 26,37,20,583 to INR 26,39,92,553. The newly issued shares will rank pari-passu with existing equity shares.